QR kód

First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer

Background: Platinum-based chemotherapy combined with immune checkpoint inhibitor therapy has recently been introduced for treating extensive-stage small-cell lung cancer (ES-SCLC). In the Phase III CASPIAN study, first-line etoposide (Etoposide) with cisplatin / carboplatin (EP) plus durvalumab sig...

Celý popis

Uloženo v:
Hlavní autoři: Eisuke Mochizuki, Shun Matsuura, Naoki Koshimizu, Suguru Kojima, Shogo Sakurai, Satoshi Kishimoto, Mitsuru Niwa, Masayuki Watanuki, Ryunosuke Inaba, Sho Takuma, Yusuke Inoue, Masato Karayama, Naoki Inui, Takafumi Suda
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2025-01-01
Edice:Cancer Treatment and Research Communications
Témata:
CASPIAN
Durvalumab
Extensive-stage small-cell lung cancer
Japanese patients
On-line přístup:http://www.sciencedirect.com/science/article/pii/S246829422500108X
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky